DiaMedica Therapeutics Inc.
$6.56
▲
0.93%
2026-04-21 06:27:00
www.diamedica.com
NCM: DMAC
Explore DiaMedica Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$369.1 M
Current Price
$6.56
52W High / Low
$10.42 / $3.28
Stock P/E
—
Book Value
$1.04
Dividend Yield
—
ROCE
-61.16%
ROE
-67.68%
Face Value
—
EPS
$-0.7
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
35
Beta
1.15
Debt / Equity
0.43
Current Ratio
11.81
Quick Ratio
11.81
Forward P/E
-7.17
Price / Sales
—
Enterprise Value
$263.11 M
EV / EBITDA
-7.66
EV / Revenue
—
Rating
Strong Buy
Target Price
$15.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Insmed Incorporated | $143.43 | — | $31.02 B | — | -55.4% | -2.49% | $212.75 / $63.81 | $3.45 |
| 2. | FibroBiologics, Inc. | $1.53 | — | $5.37 M | — | -211.82% | -4.19% | $30.6 / $1.03 | $1.85 |
| 3. | Nuvectis Pharma, Inc. | $8.33 | — | $235.78 M | — | -149.75% | -1.88% | $11.52 / $5.55 | $0.72 |
| 4. | Aardvark Therapeutics, Inc. | $5.65 | — | $114.1 M | — | -58.82% | -64.44% | $17.94 / $3.35 | $4.89 |
| 5. | Evommune, Inc. | $27.97 | — | $988.7 M | — | -39.16% | -54.42% | $33.2 / $13.88 | $6.52 |
| 6. | UroGen Pharma Ltd. | $24.92 | — | $1.21 B | — | -81.06% | 268.63% | $30 / $3.42 | $-2.18 |
| 7. | Ultragenyx Pharmaceutical Inc. | $25.06 | — | $2.39 B | — | -46.6% | -6.08% | $42.37 / $18.29 | $-0.83 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -9.21 M | -9.03 M | -8.01 M | -8.14 M | -8.42 M | — |
| Net Profit | -8.74 M | -8.62 M | -7.7 M | -7.71 M | -7.9 M | — |
| EPS in Rs | -0.16 | -0.16 | -0.14 | -0.14 | -0.15 | -0.15 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -34.4 M | -26.68 M | -21.27 M | -14 M |
| Net Profit | -32.77 M | -24.44 M | -19.38 M | -13.68 M |
| EPS in Rs | -0.61 | -0.45 | -0.36 | -0.25 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 61.37 M | 46.34 M | 54.16 M | 34.4 M |
| Total Liabilities | 5.26 M | 5.63 M | 3.1 M | 2.57 M |
| Equity | 56.11 M | 40.72 M | 51.06 M | 31.83 M |
| Current Assets | 60.63 M | 44.61 M | 53.67 M | 33.84 M |
| Current Liabilities | 5.13 M | 5.39 M | 2.79 M | 2.17 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -29.06 M | -22.08 M | -18.73 M | -11.51 M |
| Investing CF | -2.19 M | 8.56 M | -18.3 M | 11.54 M |
| Financing CF | 43.88 M | 11.99 M | 36.84 M | -0.01 M |
| Free CF | -29.1 M | -22.1 M | -18.75 M | -11.59 M |
| Capex | -0.04 M | -0.03 M | -0.02 M | -0.08 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -34.05% | -26.12% | -41.72% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.